Gain Therapeutics (GANX) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free GANX Stock Alerts $3.07 -0.12 (-3.76%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBuy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progressmarkets.businessinsider.com - April 26 at 1:25 AMHC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX)marketbeat.com - April 25 at 8:31 AMGain Therapeutics Announces Positive Phase 1 Results For GT-02287 In GBA1 Parkinson's Disease Trialmarkets.businessinsider.com - April 24 at 2:01 PMGain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Diseasefinance.yahoo.com - April 24 at 2:01 PMGain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Diseaseglobenewswire.com - April 24 at 9:25 AMGain Therapeutics' (GANX) "Outperform" Rating Reaffirmed at Oppenheimeramericanbankingnews.com - April 24 at 4:44 AMGain Therapeutics (NASDAQ:GANX) Receives Outperform Rating from Oppenheimermarketbeat.com - April 23 at 8:43 AMGain Therapeutics Inc (GANX)investing.com - April 20 at 7:29 PMHere's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisherfinance.yahoo.com - April 17 at 2:21 PMGain Therapeutics, Inc.: Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officerfinanznachrichten.de - April 8 at 12:50 PMGain Therapeutics Appoints Gene Mack As CFO; Stock Fallsmarkets.businessinsider.com - April 8 at 12:50 PMGain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officerglobenewswire.com - April 8 at 9:25 AMFormer Gildan CEO considered acquisition of Hanesbrands - Bloombergmsn.com - April 4 at 3:14 PMGain Therapeutics, Inc. (NASDAQ:GANX) Director Buys $115,800.00 in Stockinsidertrades.com - April 2 at 4:26 AMDirector Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)finance.yahoo.com - April 1 at 10:06 PMBuy Rating Affirmed for Gain Therapeutics on Promising Parkinson’s Treatment and Solid Financial Outlookmarkets.businessinsider.com - April 1 at 5:05 PMGain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officerfinance.yahoo.com - April 1 at 12:04 PMGain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 1 at 8:30 AMShort Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Increases By 16.4%marketbeat.com - March 31 at 10:55 PMOptimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson’s Drug Candidate GT-02287markets.businessinsider.com - March 28 at 1:21 AMGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Updatefinanznachrichten.de - March 27 at 5:19 AMGain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Updateglobenewswire.com - March 26 at 8:00 AMGain Therapeutics to Present at Public Ventures Discovery Dayglobenewswire.com - March 15 at 2:30 PMEXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Diseasemsn.com - March 5 at 9:15 AMGain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Diseasefinance.yahoo.com - March 5 at 9:14 AMGain Therapeutics, Inc. (NASDAQ:GANX) Sees Significant Growth in Short Interestmarketbeat.com - March 4 at 11:57 AMGain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Diseasefinance.yahoo.com - February 27 at 7:40 PMGain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Diseaseglobenewswire.com - February 27 at 2:00 PMGain Therapeutics Stock (NASDAQ:GANX), Short Interest Reportbenzinga.com - February 23 at 12:36 PMGANX Mar 2024 7.500 callfinance.yahoo.com - February 17 at 10:05 AMGain Therapeutics, Inc. (NASDAQ:GANX) Sees Large Growth in Short Interestmarketbeat.com - February 16 at 4:25 PMGain Therapeutics, Inc.: Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insightfinanznachrichten.de - February 16 at 8:51 AMGain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insightfinance.yahoo.com - February 14 at 1:07 PMGain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insightglobenewswire.com - February 14 at 12:29 PMBuy Rating for Gain Therapeutics Backed by Strong Preclinical Data and Promising Parkinson’s Candidate GT-02287markets.businessinsider.com - February 7 at 6:46 PMAmgen 4Q Revenue Surges as Acquisition Boosts Resultsmarketwatch.com - February 6 at 5:44 PMGain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Diseasefinance.yahoo.com - February 6 at 12:44 PMUPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Diseasefinance.yahoo.com - February 6 at 12:44 PMBuy Rating Affirmed: Gain Therapeutics’ Promising GT-02287 Advances Towards Key Clinical Milestones in Parkinson’s Disease Treatmentmarkets.businessinsider.com - February 1 at 10:42 PMAmgen: Debt-Funded Buybacks Constrains Future Gains Per Shareseekingalpha.com - February 1 at 7:40 AMGain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Updatefinance.yahoo.com - January 31 at 9:42 AMGain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Knowfinance.yahoo.com - January 24 at 6:08 PMGANX Gain Therapeutics, Inc.seekingalpha.com - January 17 at 6:43 PMBuy Rating Affirmed: Gain Therapeutics’ GT-02287 Shows Promise in Parkinson’s Disease Pipelinemarkets.businessinsider.com - January 4 at 4:10 PMBTIG Reaffirms Their Buy Rating on Gain Therapeutics (GANX)markets.businessinsider.com - January 3 at 2:39 PMGain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024finance.yahoo.com - January 2 at 8:49 AMDoubling Down On Gain Therapeuticsseekingalpha.com - December 22 at 6:50 PMBears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Nowfinance.yahoo.com - December 14 at 2:50 PMBuy Rating on Gain Therapeutics Backed by Promising Parkinson’s Candidate GT-02287 and Strengthened Financial Positionmarkets.businessinsider.com - December 5 at 9:51 AMGain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Researchfinance.yahoo.com - December 4 at 12:54 PM Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). GANX Media Mentions By Week GANX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GANX News Sentiment▼0.780.39▲Average Medical News Sentiment GANX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GANX Articles This Week▼101▲GANX Articles Average Week Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SCYNEXIS News Jaguar Health News Daré Bioscience News Immuneering News Apollomics News Homology Medicines News Reneo Pharmaceuticals News Vaxxinity News CalciMedica News NextCure News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GANX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
